Imatenil

Imatinib, the active ingredient in Imatenil, is a tyrosine kinase inhibitor presented as a tablet for oral use. It is indicated for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors, primarily in adult patients requiring targeted cancer therapy.

GNH USA supplies Imatenil as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, oncology centres, pharmacies and clinics worldwide through regulated distribution channels, ensuring quality assurance and compliance with EU standards, and timely delivery to meet patient needs.

Imatenil (imatinib) targets abnormal tyrosine kinase signaling in certain cancers. - Chronic Myeloid Leukemia: reduces leukemic cell proliferation and improves long‑term survival. - Gastrointestinal Stromal Tumor: inhibits tumor growth and delays disease progression. - Dermatofibrosarcoma Prot